Posts tagged global partnerships
Ladenburg starts Kindred Biosciences at buy

Ladenburg Thalmann initiated coverage of Kindred Biosciences (NASDAQ:KIN) with a “buy” rating and a $7.50 price target. The stock closed at $5.40 on Monday.

“We view Kindred as an emerging leader in development of new biologic therapies for companion animals, with two potential product launches in 2017,” writes analyst Kevin DeGeeter.

Read More